retatrutide and liver Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a trial Warning issued over counterfeit weight-loss

Adding the glucagon pathway is the feature researchers believe may give retatrutide an edge on weight loss though only further study will confirm how it compares head-to-head over the long term

Able to stimulate insulin production in the body, the hormone helps to regulate blood sugar levels and suppress appetite

Higher-risk patients include those in the dose-escalation phase, those with nausea, vomiting, bloating, abdominal pain, early satiety, or reflux symptoms, those on higher doses with GI side effects, and those with known gastroparesis or other conditions that slow gastric emptying

Another promising direction involves dissolving microneedles, which completely degrade upon administration, eliminating the need for disposal and improving patient compliance